Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scope method challenges standard liver biopsy

NCT ID NCT05118308

Knowledge-focused Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared two procedures for getting a liver biopsy and measuring liver pressure in people with chronic liver disease or cirrhosis. One method uses a scope through the mouth (endoscopic ultrasound), the other goes through a vein in the neck (transjugular). The goal was to see which approach works better and is safer. 58 adults took part, and the results will help doctors choose the best technique.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that endoscopic ultrasound is a safer or more effective way to get liver tissue and measure liver pressure, potentially changing standard practice.
What could go wrong
This is a small, completed trial with only 58 participants. Results may not apply to all patients, and the new method might not be better or could have unforeseen risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

58 people

The number who actually took part.

Started

Nov 2021

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age above 18 years * Undergoing evaluation for chronic liver disease or portal hypertension * Planned to undergo a liver biopsy and HVPG by their treating hepatologist for clinical purposes * Signed informed consent Exclusion Criteria: * Uncorrectable coagulopathy (INR above 1.5) * Uncorrectable thrombocytopenia (Platelets under 50,000) * Anticoagulation or antiplatelet therapy that cannot be discontinued * Surgically altered upper digestive anatomy * Biliary obstruction * Grade II ascites or more * Intrahepatic portal vein thrombosis * Previous liver transplantation * Past hypersensitivity reaction to midazolam or ketamine * History of psychotic disorder * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis liver disorder portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic liver disease Cirrhosis Portal hypertension

Contacts and locations

Locations

  • McGill University Health Centre

    Montreal, Quebec, H3G1A4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.